


Last Erythropoiesis-Stimulating Agent treatment:Darbepoetin alfa
Categories:Low (<= 7.5 ug/week)




Last Erythropoiesis-Stimulating Agent treatment:Darbepoetin alfa
Categories:Low (<= 7.5 ug/week)




Last Erythropoiesis-Stimulating Agent treatment:Darbepoetin alfa
Categories:High (> 7.5 ug/week)




Last Erythropoiesis-Stimulating Agent treatment:Darbepoetin alfa
Categories:High (> 7.5 ug/week)




Last Erythropoiesis-Stimulating Agent treatment:Darbepoetin alfa
Categories:Total




Last Erythropoiesis-Stimulating Agent treatment:Darbepoetin alfa
Categories:Total




Last Erythropoiesis-Stimulating Agent treatment:Epoetin beta pegol
Categories:Low (<= 6.25 ug/week)




Last Erythropoiesis-Stimulating Agent treatment:Epoetin beta pegol
Categories:Low (<= 6.25 ug/week)




Last Erythropoiesis-Stimulating Agent treatment:Epoetin beta pegol
Categories:High (> 6.25 ug/week)



Last Erythropoiesis-Stimulating Agent treatment:Epoetin beta pegol
Categories:High (> 6.25 ug/week)








図 2.7.3.6-28　前治療として使用した ESA の種類別の各来院での平均用量（試験 19350、SAF）

表 2.7.3.6-69 前治療として使用した ESA の種類別の各来院での平均用量（試験 19350、SAF）

Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: Low (<= 7.5 ug/week)

		Value at visit (mg)					
Actual Treatment	Visit	n	Mean	SD	Min	Median	Max
Molidustat (N=16)	Week 0	16	25.00	0.00	25.0	25.00	25.0
	Week 2	16	25.00	0.00	25.0	25.00	25.0
	Week 4	16	31.25	11.18	25.0	25.00	50.0
	Week 8	16	31.25	22.82	0.0	25.00	75.0
	Week 12	16	33.13	27.35	0.0	25.00	100.0
	Week 16	16	32.34	28.14	0.0	25.00	100.0
	Week 20	16	35.00	25.59	5.0	25.00	75.0
	Week 24	15	29.00	28.27	0.0	25.00	100.0
	Week 28	13	24.81	28.44	0.0	25.00	100.0
	Week 30	13	26.15	27.38	0.0	25.00	100.0
	Week 32	13	23.27	28.51	0.0	12.50	100.0
	Week 34	13	23.27	28.51	0.0	12.50	100.0
	Week 36	13	27.12	28.48	0.0	12.50	100.0
	Week 40	13	25.19	23.57	0.0	12.50	75.0
	Week 44	13	22.88	19.68	0.0	12.50	50.0
	Week 48	13	18.08	19.48	0.0	12.50	50.0
Darbepoetin alfa (N=15)	Week 0	15	7.25	0.97	3.8	7.50	7.5
	Week 2	15	7.25	0.97	3.8	7.50	7.5
	Week 4	15	9.75	3.96	3.8	7.50	15.0
	Week 8	15	12.25	7.01	3.8	7.50	22.5
	Week 12	15	13.00	8.13	3.8	7.50	30.0
	Week 16	15	13.25	10.78	3.8	7.50	45.0
	Week 20	15	12.50	11.04	3.8	7.50	45.0
	Week 24	14	11.25	11.10	3.8	7.50	45.0
	Week 28	14	11.79	11.47	3.8	7.50	45.0
	Week 30	14	11.79	11.47	3.8	7.50	45.0
	Week 32	14	13.39	12.37	3.8	7.50	45.0
	Week 34	13	13.27	12.86	3.8	7.50	45.0
	Week 36	13	13.27	13.92	0.0	7.50	45.0
	Week 40	13	14.42	15.90	0.0	7.50	45.0
	Week 44	13	14.42	15.90	0.0	7.50	45.0
	Week 48	13	15.87	15.40	0.0	7.50	45.0

Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: High (> 7.5 ug/week)

		Value at visit (mg)					
Actual Treatment	Visit	n	Mean	SD	Min	Median	Max
Molidustat (N=19)	Week 0	19	48.68	5.74	25.0	50.00	50.0
	Week 2	19	48.68	5.74	25.0	50.00	50.0
	Week 4	19	60.53	17.31	25.0	75.00	75.0
	Week 8	19	68.42	31.00	0.0	75.00	100.0
	Week 12	18	68.75	44.19	0.0	75.00	150.0
	Week 16	18	56.53	60.71	0.0	37.50	200.0
	Week 20	18	55.14	63.52	0.0	37.50	200.0
	Week 24	18	49.58	60.63	0.0	25.00	200.0
	Week 28	17	45.88	40.88	0.0	25.00	150.0
	Week 30	17	47.35	39.55	5.0	25.00	150.0
	Week 32	16	45.31	28.82	0.0	50.00	100.0
	Week 34	17	42.94	29.57	0.0	50.00	100.0
	Week 36	17	56.62	28.34	12.5	50.00	100.0
	Week 40	17	44.85	35.92	0.0	50.00	100.0
	Week 44	16	48.75	27.16	5.0	50.00	100.0
	Week 48	16	44.84	31.83	0.0	50.00	100.0
Darbepoetin alfa (N=30)	Week 0	30	17.50	7.96	7.5	15.00	45.0
	Week 2	30	18.00	8.26	7.5	15.00	45.0
	Week 4	30	17.75	7.75	0.0	15.00	30.0
	Week 8	30	21.38	10.19	0.0	22.50	45.0
	Week 12	28	25.98	14.65	0.0	22.50	45.0
	Week 16	26	29.71	15.66	0.0	26.25	60.0
	Week 20	25	31.50	18.87	0.0	30.00	90.0
	Week 24	25	26.70	14.21	0.0	30.00	45.0
	Week 28	25	27.45	15.34	3.8	22.50	60.0
	Week 30	25	26.85	14.27	3.8	22.50	45.0
	Week 32	25	25.05	15.49	0.0	22.50	45.0
	Week 34	25	26.85	15.07	0.0	30.00	45.0
	Week 36	25	26.85	13.76	3.8	30.00	45.0
	Week 40	24	26.41	14.56	0.0	22.50	45.0
	Week 44	24	28.91	16.97	3.8	22.50	60.0
	Week 48	21	27.14	14.85	3.8	22.50	45.0

Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: Total

		Value at visit (mg)					
Actual Treatment	Visit	n	Mean	SD	Min	Median	Max
Molidustat (N=35)	Week 0	35	37.86	12.68	25.0	50.00	50.0
	Week 2	35	37.86	12.68	25.0	50.00	50.0
	Week 4	35	47.14	20.80	25.0	50.00	75.0
	Week 8	35	51.43	33.04	0.0	50.00	100.0
	Week 12	34	51.99	40.89	0.0	50.00	150.0
	Week 16	34	45.15	49.08	0.0	25.00	200.0
	Week 20	34	45.66	49.80	0.0	25.00	200.0
	Week 24	33	40.23	49.10	0.0	25.00	200.0
	Week 28	30	36.75	37.01	0.0	25.00	150.0
	Week 30	30	38.17	35.88	0.0	25.00	150.0
	Week 32	29	35.43	30.30	0.0	25.00	100.0
	Week 34	30	34.42	30.28	0.0	25.00	100.0
	Week 36	30	43.83	31.62	0.0	50.00	100.0
	Week 40	30	36.33	32.25	0.0	25.00	100.0
	Week 44	29	37.16	27.06	0.0	50.00	100.0
	Week 48	29	32.84	29.81	0.0	25.00	100.0
Darbepoetin alfa (N=45)	Week 0	45	14.08	8.12	3.8	15.00	45.0
	Week 2	45	14.42	8.46	3.8	15.00	45.0
	Week 4	45	15.08	7.69	0.0	15.00	30.0
	Week 8	45	18.33	10.15	0.0	15.00	45.0
	Week 12	43	21.45	14.11	0.0	15.00	45.0
	Week 16	41	23.69	16.07	0.0	22.50	60.0
	Week 20	40	24.38	18.70	0.0	22.50	90.0
	Week 24	39	21.15	15.04	0.0	15.00	45.0
	Week 28	39	21.83	15.86	3.8	15.00	60.0
	Week 30	39	21.44	15.07	3.8	15.00	45.0
	Week 32	39	20.87	15.36	0.0	15.00	45.0
	Week 34	38	22.20	15.61	0.0	22.50	45.0
	Week 36	38	22.20	15.11	0.0	22.50	45.0
	Week 40	37	22.20	15.92	0.0	22.50	45.0
	Week 44	37	23.82	17.81	0.0	22.50	60.0
	Week 48	34	22.83	15.84	0.0	22.50	45.0

Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: Low (<= 6.25 ug/week)

		Value at visit (mg)					
Actual Treatment	Visit	n	Mean	SD	Min	Median	Max
Molidustat (N=10)	Week 0	10	25.00	0.00	25.0	25.00	25.0
	Week 2	10	25.00	0.00	25.0	25.00	25.0
	Week 4	10	35.00	17.48	0.0	37.50	50.0
	Week 8	10	47.50	29.93	0.0	50.00	75.0
	Week 12	9	44.44	34.86	0.0	50.00	100.0
	Week 16	9	37.50	31.25	0.0	25.00	75.0
	Week 20	9	36.11	27.56	0.0	25.00	75.0
	Week 24	9	36.11	24.56	0.0	50.00	75.0
	Week 28	9	38.06	25.67	5.0	25.00	75.0
	Week 30	9	38.06	25.67	5.0	25.00	75.0
	Week 32	9	38.89	32.74	0.0	25.00	100.0
	Week 34	9	36.11	27.56	0.0	25.00	75.0
	Week 36	9	29.72	24.32	0.0	25.00	75.0
	Week 40	8	31.25	17.68	0.0	25.00	50.0
	Week 44	8	37.50	23.15	0.0	37.50	75.0
	Week 48	8	37.50	26.73	0.0	50.00	75.0
Darbepoetin alfa (N=9)	Week 0	9	3.75	0.00	3.8	3.75	3.8
	Week 2	9	3.75	0.00	3.8	3.75	3.8
	Week 4	9	5.42	1.98	3.8	3.75	7.5
	Week 8	9	7.92	4.38	3.8	7.50	15.0
	Week 12	9	11.67	7.37	3.8	7.50	22.5
	Week 16	9	15.00	10.44	3.8	15.00	30.0
	Week 20	9	17.92	16.75	0.0	15.00	45.0
	Week 24	9	19.58	20.18	0.0	15.00	60.0
	Week 28	9	16.67	28.50	0.0	7.50	90.0
	Week 30	9	13.33	19.04	0.0	7.50	60.0
	Week 32	9	11.25	10.27	0.0	7.50	30.0
	Week 34	9	11.25	10.27	0.0	7.50	30.0
	Week 36	9	10.00	10.44	0.0	7.50	30.0
	Week 40	9	9.17	9.58	0.0	7.50	30.0
	Week 44	9	9.17	9.58	0.0	7.50	30.0
	Week 48	9	5.83	5.96	0.0	3.75	15.0


Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: High (> 6.25 ug/week)

Actual Treatment	Visit	Value at visit (mg)					
		n	Mean	SD	Min	Median	Max
Molidustat (N=37)	Week 0	37	48.65	8.22	0.0	50.00	50.0
	Week 2	36	49.31	4.17	25.0	50.00	50.0
	Week 4	36	59.03	19.96	0.0	75.00	75.0
	Week 8	35	67.50	29.42	0.0	75.00	100.0
	Week 12	35	76.07	51.84	0.0	75.00	150.0
	Week 16	33	73.26	62.65	0.0	50.00	200.0
	Week 20	32	68.91	61.31	0.0	50.00	200.0
	Week 24	31	64.68	55.91	0.0	50.00	200.0
	Week 28	30	58.50	54.09	0.0	50.00	200.0
	Week 30	28	51.07	44.15	0.0	50.00	200.0
	Week 32	27	51.30	38.89	5.0	50.00	150.0
	Week 34	27	43.89	35.14	0.0	50.00	150.0
	Week 36	26	44.62	35.63	0.0	50.00	150.0
	Week 40	25	47.40	29.85	5.0	50.00	100.0
	Week 44	23	45.00	35.18	0.0	50.00	150.0
	Week 48	22	43.07	33.42	0.0	50.00	150.0
Darbepoetin alfa (N=28)	Week 0	28	16.34	8.43	7.5	18.75	30.0
	Week 2	28	16.34	8.43	7.5	18.75	30.0
	Week 4	27	18.61	9.62	7.5	15.00	45.0
	Week 8	27	22.64	12.76	3.8	22.50	45.0
	Week 12	26	26.39	15.39	3.8	22.50	60.0
	Week 16	26	31.30	18.70	3.8	30.00	90.0
	Week 20	25	30.30	16.70	7.5	30.00	60.0
	Week 24	24	28.59	17.02	0.0	30.00	60.0
	Week 28	22	30.00	18.04	3.8	30.00	60.0
	Week 30	22	30.68	21.04	3.8	30.00	90.0
	Week 32	21	31.96	23.10	3.8	30.00	90.0
	Week 34	21	30.54	21.68	3.8	30.00	90.0
	Week 36	21	31.61	21.43	3.8	30.00	90.0
	Week 40	20	26.25	23.28	0.0	18.75	90.0
	Week 44	20	33.00	25.33	0.0	26.25	90.0
	Week 48	20	36.19	28.31	0.0	26.25	90.0


Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: Total

Actual Treatment	Visit	Value at visit (mg)					
		n	Mean	SD	Min	Median	Max
Molidustat (N=47)	Week 0	47	43.62	12.19	0.0	50.00	50.0
	Week 2	46	44.02	10.78	25.0	50.00	50.0
	Week 4	46	53.80	21.71	0.0	50.00	75.0
	Week 8	45	63.06	30.38	0.0	75.00	100.0
	Week 12	44	69.60	50.17	0.0	50.00	150.0
	Week 16	42	65.60	58.94	0.0	50.00	200.0
	Week 20	41	61.71	57.04	0.0	50.00	200.0
	Week 24	40	58.25	51.71	0.0	50.00	200.0
	Week 28	39	53.78	49.48	0.0	50.00	200.0
	Week 30	37	47.91	40.50	0.0	50.00	200.0
	Week 32	36	48.19	37.39	0.0	50.00	150.0
	Week 34	36	41.94	33.20	0.0	37.50	150.0
	Week 36	35	40.79	33.41	0.0	25.00	150.0
	Week 40	33	43.48	28.03	0.0	50.00	100.0
	Week 44	31	43.06	32.31	0.0	50.00	150.0
	Week 48	30	41.58	31.43	0.0	50.00	150.0
Darbepoetin alfa (N=37)	Week 0	37	13.28	9.13	3.8	7.50	30.0
	Week 2	37	13.28	9.13	3.8	7.50	30.0
	Week 4	36	15.31	10.16	3.8	15.00	45.0
	Week 8	36	18.96	12.93	3.8	15.00	45.0
	Week 12	35	22.61	15.15	3.8	22.50	60.0
	Week 16	35	27.11	18.31	3.8	22.50	90.0
	Week 20	34	27.02	17.36	0.0	22.50	60.0
	Week 24	33	26.14	18.07	0.0	22.50	60.0
	Week 28	31	26.13	21.96	0.0	22.50	90.0
	Week 30	31	25.65	21.70	0.0	22.50	90.0
	Week 32	30	25.75	22.15	0.0	22.50	90.0
	Week 34	30	24.75	20.83	0.0	22.50	90.0
	Week 36	30	25.13	21.17	0.0	18.75	90.0
	Week 40	29	20.95	21.41	0.0	15.00	90.0
	Week 44	29	25.60	24.24	0.0	15.00	90.0
	Week 48	29	26.77	27.53	0.0	15.00	90.0


Last Erythropoiesis-Stimulating Agent treatment:Darbepoetin alfa
Categories:Low (<= 7.5 ug/week)




Last Erythropoiesis-Stimulating Agent treatment:Darbepoetin alfa
Categories:Low (<= 7.5 ug/week)




Last Erythropoiesis-Stimulating Agent treatment:Darbepoetin alfa
Categories:High (> 7.5 ug/week)




Last Erythropoiesis-Stimulating Agent treatment:Darbepoetin alfa
Categories:High (> 7.5 ug/week)




Last Erythropoiesis-Stimulating Agent treatment:Darbepoetin alfa
Categories:Total




Last Erythropoiesis-Stimulating Agent treatment:Darbepoetin alfa
Categories:Total




Last Erythropoiesis-Stimulating Agent treatment:Epoetin beta pegol
Categories:Low (<= 6.25 ug/week)




Last Erythropoiesis-Stimulating Agent treatment:Epoetin beta pegol
Categories:Low (<= 6.25 ug/week)




Last Erythropoiesis-Stimulating Agent treatment:Epoetin beta pegol
Categories:High (> 6.25 ug/week)



Last Erythropoiesis-Stimulating Agent treatment:Epoetin beta pegol
Categories:High (> 6.25 ug/week)








図 2.7.3.6-29　前治療として使用した ESA の種類別の各来院での用量の分布（試験 19350、SAF）

表 2.7.3.6-70　前治療として使用したESAの種類別のモリデュスタットの各来院での用量の分布（試験19350、SAF）

Actual Treatment: Molidustat
Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: Low (<= 7.5 ug/week)

Visit	n	0 mg	5 mg	12.5 mg	25 mg	50 mg	75 mg	100 mg
Week 0	16	0	0	0	16 (100.0%)	0	0	0
Week 2	16	0	0	0	16 (100.0%)	0	0	0
Week 4	16	0	0	0	12 (75.0%)	4 (25.0%)	0	0
Week 8	16	2 (12.5%)	0	2 (12.5%)	7 (43.8%)	3 (18.8%)	2 (12.5%)	0
Week 12	16	1 (6.3%)	1 (6.3%)	4 (25.0%)	4 (25.0%)	4 (25.0%)	1 (6.3%)	1 (6.3%)
Week 16	16	2 (12.5%)	1 (6.3%)	3 (18.8%)	4 (25.0%)	4 (25.0%)	1 (6.3%)	1 (6.3%)
Week 20	16	0	2 (12.5%)	4 (25.0%)	3 (18.8%)	4 (25.0%)	3 (18.8%)	0
Week 24	15	1 (6.7%)	2 (13.3%)	4 (26.7%)	4 (26.7%)	2 (13.3%)	1 (6.7%)	1 (6.7%)
Week 28	13	3 (23.1%)	2 (15.4%)	1 (7.7%)	4 (30.8%)	2 (15.4%)	0	1 (7.7%)
Week 30	13	1 (7.7%)	3 (23.1%)	2 (15.4%)	4 (30.8%)	2 (15.4%)	0	1 (7.7%)
Week 32	13	2 (15.4%)	3 (23.1%)	3 (23.1%)	2 (15.4%)	2 (15.4%)	0	1 (7.7%)
Week 34	13	2 (15.4%)	3 (23.1%)	3 (23.1%)	2 (15.4%)	2 (15.4%)	0	1 (7.7%)
Week 36	13	1 (7.7%)	3 (23.1%)	3 (23.1%)	2 (15.4%)	3 (23.1%)	0	1 (7.7%)
Week 40	13	1 (7.7%)	3 (23.1%)	3 (23.1%)	2 (15.4%)	3 (23.1%)	1 (7.7%)	0
Week 44	13	1 (7.7%)	2 (15.4%)	5 (38.5%)	1 (7.7%)	4 (30.8%)	0	0
Week 48	13	3 (23.1%)	2 (15.4%)	4 (30.8%)	1 (7.7%)	3 (23.1%)	0	0

Actual Treatment: Molidustat
Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: High (> 7.5 ug/week)

Visit	n	0 mg	5 mg	12.5 mg	25 mg	50 mg	75 mg	100 mg	150 mg	200 mg
Week 0	19	0	0	0	1 (5.3%)	18 (94.7%)	0	0	0	0
Week 2	19	0	0	0	1 (5.3%)	18 (94.7%)	0	0	0	0
Week 4	19	0	0	0	2 (10.5%)	7 (36.8%)	10 (52.6%)	0	0	0
Week 8	19	1 (5.3%)	0	0	2 (10.5%)	5 (26.3%)	4 (21.1%)	7 (36.8%)	0	0
Week 12	18	2 (11.1%)	0	1 (5.6%)	1 (5.6%)	4 (22.2%)	4 (22.2%)	4 (22.2%)	2 (11.1%)	0
Week 16	18	3 (16.7%)	1 (5.6%)	1 (5.6%)	4 (22.2%)	2 (11.1%)	4 (22.2%)	1 (5.6%)	0	2 (11.1%)
Week 20	18	3 (16.7%)	1 (5.6%)	1 (5.6%)	4 (22.2%)	5 (27.8%)	1 (5.6%)	0	1 (5.6%)	2 (11.1%)
Week 24	18	3 (16.7%)	1 (5.6%)	3 (16.7%)	3 (16.7%)	3 (16.7%)	3 (16.7%)	0	0	2 (11.1%)
Week 28	17	1 (5.9%)	1 (5.9%)	4 (23.5%)	3 (17.6%)	2 (11.8%)	4 (23.5%)	1 (5.9%)	1 (5.9%)	0
Week 30	17	0	1 (5.9%)	4 (23.5%)	4 (23.5%)	2 (11.8%)	4 (23.5%)	1 (5.9%)	1 (5.9%)	0
Week 32	16	1 (6.3%)	0	2 (12.5%)	4 (25.0%)	4 (25.0%)	4 (25.0%)	1 (6.3%)	0	0
Week 34	17	1 (5.9%)	1 (5.9%)	2 (11.8%)	4 (23.5%)	4 (23.5%)	4 (23.5%)	1 (5.9%)	0	0
Week 36	17	0	0	3 (17.6%)	1 (5.9%)	5 (29.4%)	6 (35.3%)	2 (11.8%)	0	0
Week 40	17	3 (17.6%)	0	3 (17.6%)	2 (11.8%)	2 (11.8%)	5 (29.4%)	2 (11.8%)	0	0
Week 44	16	0	1 (6.3%)	2 (12.5%)	2 (12.5%)	6 (37.5%)	4 (25.0%)	1 (6.3%)	0	0
Week 48	16	1 (6.3%)	1 (6.3%)	3 (18.8%)	2 (12.5%)	3 (18.8%)	5 (31.3%)	1 (6.3%)	0	0

Actual Treatment: Molidustat
Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: Total

Visit	n	0 mg	5 mg	12.5 mg	25 mg	50 mg	75 mg	100 mg	150 mg	200 mg
Week 0	35	0	0	0	17 (48.6%)	18 (51.4%)	0	0	0	0
Week 2	35	0	0	0	17 (48.6%)	18 (51.4%)	0	0	0	0
Week 4	35	0	0	0	14 (40.0%)	11 (31.4%)	10 (28.6%)	0	0	0
Week 8	35	3 (8.6%)	0	2 (5.7%)	9 (25.7%)	8 (22.9%)	6 (17.1%)	7 (20.0%)	0	0
Week 12	34	3 (8.8%)	1 (2.9%)	5 (14.7%)	5 (14.7%)	8 (23.5%)	5 (14.7%)	5 (14.7%)	2 (5.9%)	0
Week 16	34	5 (14.7%)	2 (5.9%)	4 (11.8%)	8 (23.5%)	6 (17.6%)	5 (14.7%)	2 (5.9%)	0	2 (5.9%)
Week 20	34	3 (8.8%)	3 (8.8%)	5 (14.7%)	7 (20.6%)	9 (26.5%)	4 (11.8%)	0	1 (2.9%)	2 (5.9%)
Week 24	33	4 (12.1%)	3 (9.1%)	7 (21.2%)	7 (21.2%)	5 (15.2%)	4 (12.1%)	1 (3.0%)	0	2 (6.1%)
Week 28	30	4 (13.3%)	3 (10.0%)	5 (16.7%)	7 (23.3%)	4 (13.3%)	4 (13.3%)	2 (6.7%)	1 (3.3%)	0
Week 30	30	1 (3.3%)	4 (13.3%)	6 (20.0%)	8 (26.7%)	4 (13.3%)	4 (13.3%)	2 (6.7%)	1 (3.3%)	0
Week 32	29	3 (10.3%)	3 (10.3%)	5 (17.2%)	6 (20.7%)	6 (20.7%)	4 (13.8%)	2 (6.9%)	0	0
Week 34	30	3 (10.0%)	4 (13.3%)	5 (16.7%)	6 (20.0%)	6 (20.0%)	4 (13.3%)	2 (6.7%)	0	0
Week 36	30	1 (3.3%)	3 (10.0%)	6 (20.0%)	3 (10.0%)	8 (26.7%)	6 (20.0%)	3 (10.0%)	0	0
Week 40	30	4 (13.3%)	3 (10.0%)	6 (20.0%)	4 (13.3%)	5 (16.7%)	6 (20.0%)	2 (6.7%)	0	0
Week 44	29	1 (3.4%)	3 (10.3%)	7 (24.1%)	3 (10.3%)	10 (34.5%)	4 (13.8%)	1 (3.4%)	0	0
Week 48	29	4 (13.8%)	3 (10.3%)	7 (24.1%)	3 (10.3%)	6 (20.7%)	5 (17.2%)	1 (3.4%)	0	0

Actual Treatment: Molidustat
Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: Low (<= 6.25 ug/week)

Visit	n	0 mg	5 mg	12.5 mg	25 mg	50 mg	75 mg	100 mg
Week 0	10	0	0	0	10 (100.0%)	0	0	0
Week 2	10	0	0	0	10 (100.0%)	0	0	0
Week 4	10	1 (10.0%)	0	0	4 (40.0%)	5 (50.0%)	0	0
Week 8	10	2 (20.0%)	0	0	1 (10.0%)	3 (30.0%)	4 (40.0%)	0
Week 12	9	2 (22.2%)	0	0	2 (22.2%)	2 (22.2%)	2 (22.2%)	1 (11.1%)
Week 16	9	1 (11.1%)	0	3 (33.3%)	1 (11.1%)	1 (11.1%)	3 (33.3%)	0
Week 20	9	1 (11.1%)	0	2 (22.2%)	2 (22.2%)	2 (22.2%)	2 (22.2%)	0
Week 24	9	1 (11.1%)	0	2 (22.2%)	1 (11.1%)	4 (44.4%)	1 (11.1%)	0
Week 28	9	0	1 (11.1%)	1 (11.1%)	3 (33.3%)	2 (22.2%)	2 (22.2%)	0
Week 30	9	0	1 (11.1%)	1 (11.1%)	3 (33.3%)	2 (22.2%)	2 (22.2%)	0
Week 32	9	1 (11.1%)	0	2 (22.2%)	2 (22.2%)	2 (22.2%)	1 (11.1%)	1 (11.1%)
Week 34	9	1 (11.1%)	0	2 (22.2%)	2 (22.2%)	2 (22.2%)	2 (22.2%)	0
Week 36	9	1 (11.1%)	1 (11.1%)	1 (11.1%)	3 (33.3%)	2 (22.2%)	1 (11.1%)	0
Week 40	8	1 (12.5%)	0	0	4 (50.0%)	3 (37.5%)	0	0
Week 44	8	1 (12.5%)	0	0	3 (37.5%)	3 (37.5%)	1 (12.5%)	0
Week 48	8	2 (25.0%)	0	0	1 (12.5%)	4 (50.0%)	1 (12.5%)	0


Actual Treatment: Molidustat
Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: High (> 6.25 ug/week)

Visit	n	0 mg	5 mg	12.5 mg	25 mg	50 mg	75 mg	100 mg	150 mg	200 mg
Week 0	37	1 (2.7%)	0	0	0	36 (97.3%)	0	0	0	0
Week 2	36	0	0	0	1 (2.8%)	35 (97.2%)	0	0	0	0
Week 4	36	1 (2.8%)	0	0	4 (11.1%)	12 (33.3%)	19 (52.8%)	0	0	0
Week 8	35	1 (2.9%)	0	1 (2.9%)	3 (8.6%)	11 (31.4%)	7 (20.0%)	12 (34.3%)	0	0
Week 12	35	3 (8.6%)	0	1 (2.9%)	5 (14.3%)	8 (22.9%)	5 (14.3%)	4 (11.4%)	9 (25.7%)	0
Week 16	33	3 (9.1%)	1 (3.0%)	1 (3.0%)	8 (24.2%)	5 (15.2%)	4 (12.1%)	3 (9.1%)	5 (15.2%)	3 (9.1%)
Week 20	32	2 (6.3%)	1 (3.1%)	2 (6.3%)	7 (21.9%)	8 (25.0%)	2 (6.3%)	5 (15.6%)	1 (3.1%)	4 (12.5%)
Week 24	31	1 (3.2%)	1 (3.2%)	2 (6.5%)	7 (22.6%)	10 (32.3%)	2 (6.5%)	4 (12.9%)	1 (3.2%)	3 (9.7%)
Week 28	30	3 (10.0%)	1 (3.3%)	0	9 (30.0%)	8 (26.7%)	3 (10.0%)	2 (6.7%)	2 (6.7%)	2 (6.7%)
Week 30	28	2 (7.1%)	1 (3.6%)	0	10 (35.7%)	8 (28.6%)	3 (10.7%)	2 (7.1%)	1 (3.6%)	1 (3.6%)
Week 32	27	0	2 (7.4%)	2 (7.4%)	8 (29.6%)	7 (25.9%)	4 (14.8%)	2 (7.4%)	2 (7.4%)	0
Week 34	27	2 (7.4%)	2 (7.4%)	2 (7.4%)	7 (25.9%)	8 (29.6%)	3 (11.1%)	2 (7.4%)	1 (3.7%)	0
Week 36	26	2 (7.7%)	2 (7.7%)	2 (7.7%)	6 (23.1%)	8 (30.8%)	3 (11.5%)	2 (7.7%)	1 (3.8%)	0
Week 40	25	0	2 (8.0%)	4 (16.0%)	3 (12.0%)	9 (36.0%)	4 (16.0%)	3 (12.0%)	0	0
Week 44	23	1 (4.3%)	2 (8.7%)	4 (17.4%)	2 (8.7%)	9 (39.1%)	3 (13.0%)	1 (4.3%)	1 (4.3%)	0
Week 48	22	1 (4.5%)	2 (9.1%)	3 (13.6%)	3 (13.6%)	9 (40.9%)	3 (13.6%)	0	1 (4.5%)	0

Actual Treatment: Molidustat
Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: Total


Visit	n	0 mg	5 mg	12.5 mg	25 mg	50 mg	75 mg	100 mg	150 mg	200 mg
Week 0	47	1 (2.1%)	0	0	10 (21.3%)	36 (76.6%)	0	0	0	0
Week 2	46	0	0	0	11 (23.9%)	35 (76.1%)	0	0	0	0
Week 4	46	2 (4.3%)	0	0	8 (17.4%)	17 (37.0%)	19 (41.3%)	0	0	0
Week 8	45	3 (6.7%)	0	1 (2.2%)	4 (8.9%)	14 (31.1%)	11 (24.4%)	12 (26.7%)	0	0
Week 12	44	5 (11.4%)	0	1 (2.3%)	7 (15.9%)	10 (22.7%)	7 (15.9%)	5 (11.4%)	9 (20.5%)	0
Week 16	42	4 (9.5%)	1 (2.4%)	4 (9.5%)	9 (21.4%)	6 (14.3%)	7 (16.7%)	3 (7.1%)	5 (11.9%)	3 (7.1%)
Week 20	41	3 (7.3%)	1 (2.4%)	4 (9.8%)	9 (22.0%)	10 (24.4%)	4 (9.8%)	5 (12.2%)	1 (2.4%)	4 (9.8%)
Week 24	40	2 (5.0%)	1 (2.5%)	4 (10.0%)	8 (20.0%)	14 (35.0%)	3 (7.5%)	4 (10.0%)	1 (2.5%)	3 (7.5%)
Week 28	39	3 (7.7%)	2 (5.1%)	1 (2.6%)	12 (30.8%)	10 (25.6%)	5 (12.8%)	2 (5.1%)	2 (5.1%)	2 (5.1%)
Week 30	37	2 (5.4%)	2 (5.4%)	1 (2.7%)	13 (35.1%)	10 (27.0%)	5 (13.5%)	2 (5.4%)	1 (2.7%)	1 (2.7%)
Week 32	36	1 (2.8%)	2 (5.6%)	4 (11.1%)	10 (27.8%)	9 (25.0%)	5 (13.9%)	3 (8.3%)	2 (5.6%)	0
Week 34	36	3 (8.3%)	2 (5.6%)	4 (11.1%)	9 (25.0%)	10 (27.8%)	5 (13.9%)	2 (5.6%)	1 (2.8%)	0
Week 36	35	3 (8.6%)	3 (8.6%)	3 (8.6%)	9 (25.7%)	10 (28.6%)	4 (11.4%)	2 (5.7%)	1 (2.9%)	0
Week 40	33	1 (3.0%)	2 (6.1%)	4 (12.1%)	7 (21.2%)	12 (36.4%)	4 (12.1%)	3 (9.1%)	0	0
Week 44	31	2 (6.5%)	2 (6.5%)	4 (12.9%)	5 (16.1%)	12 (38.7%)	4 (12.9%)	1 (3.2%)	1 (3.2%)	0
Week 48	30	3 (10.0%)	2 (6.7%)	3 (10.0%)	4 (13.3%)	13 (43.3%)	4 (13.3%)	0	1 (3.3%)	0

Last Erythropoiesis-Stimulating Agent treatment:Darbepoetin alfa
Categories:Total



The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0

Last Erythropoiesis-Stimulating Agent treatment:Epoetin beta pegol
Categories:Total



The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0




図 2.7.3.6-30 前治療として使用した ESA の種類別（DA、PEGOL 又は rHuEPO）の各来院時の平均 Hb 値（g/dL、平均値±SD）の推移（試験 19352、FAS）

表 2.7.3.6-71　前治療として使用した ESA の種類別（DA、PEGOL 又は rHuEPO）の各来院時の平均 Hb 値（g/dL、平均値±SD）の推移（試験 19352、FAS）

Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: Total

		Value at visit						Change from Baseline					
Planned Treatment	Visit	n	Mean	SD	Min	Median	Max	n	Mean	SD	Min	Median	Max
Molidustat (N=86)	Screening -6	1	12.40	.	12.4	12.40	12.4						
	Screening -5	1	12.20	.	12.2	12.20	12.2						
	Screening -4	4	11.00	1.28	9.1	11.55	11.8						
	Screening -3	13	11.09	1.06	9.5	11.50	12.5						
	Screening -2	86	10.87	0.72	9.3	10.90	12.2						
	Screening -1	86	10.93	0.64	9.6	11.00	12.5						
	Week 0	86	10.83	0.71	9.3	10.90	12.1						
	Baseline	86	10.88	0.64	9.6	10.90	11.9						
	Week 2	84	10.71	0.84	8.6	10.80	12.2	84	-0.17	0.59	-1.8	-0.17	1.3
	Week 4	83	10.51	1.10	8.0	10.60	12.6	83	-0.38	1.01	-3.5	-0.27	2.7
	Week 6	81	10.34	1.31	7.1	10.50	13.4	81	-0.57	1.28	-3.8	-0.43	3.5
	Week 8	78	10.37	1.30	7.6	10.65	12.5	78	-0.53	1.30	-3.3	-0.28	2.6
	Week 10	76	10.47	1.30	7.6	10.70	13.1	76	-0.43	1.31	-3.4	-0.31	2.1
	Week 12	75	10.51	1.35	7.4	10.70	12.8	75	-0.41	1.38	-3.8	-0.17	2.5
	Week 14	71	10.72	1.32	8.1	10.90	13.5	71	-0.20	1.36	-3.3	-0.13	2.7
	Week 16	70	10.89	1.20	8.2	11.10	12.9	70	-0.03	1.31	-3.5	0.10	3.3
	Week 18	69	11.04	1.05	8.7	11.10	13.3	69	0.10	1.19	-3.1	0.07	2.7
	Week 20	69	11.16	1.02	8.4	11.20	13.4	69	0.22	1.14	-3.4	0.27	2.9
	Week 22	69	11.24	0.74	9.0	11.20	12.7	69	0.30	0.91	-2.8	0.20	3.1
	Week 24	67	11.26	0.85	9.3	11.30	13.4	67	0.30	0.99	-2.4	0.30	3.8
	Week 26	69	11.23	0.90	9.1	11.20	13.7	69	0.30	1.11	-2.2	0.30	4.1
	Week 28	68	11.26	0.86	9.2	11.30	13.1	68	0.32	1.05	-2.0	0.35	2.9
	Week 30	67	11.17	0.83	8.9	11.30	13.4	67	0.23	0.96	-1.9	0.27	2.5
	Week 32	67	11.13	0.85	9.1	11.10	12.9	67	0.18	0.98	-1.8	0.27	2.3
	Week 33	66	11.08	0.88	9.2	11.25	12.7	66	0.14	1.00	-1.8	0.27	2.4
	Week 34	66	11.04	0.87	8.9	11.05	12.6	66	0.09	1.00	-1.9	0.05	2.4
	Week 35	66	10.94	0.92	8.8	11.10	12.5	66	-0.01	1.05	-1.9	0.03	2.2
	Week 36	65	10.90	0.88	8.8	11.10	12.5	65	-0.05	1.03	-1.9	-0.20	2.1
	Week 38	66	10.87	0.87	8.4	10.80	12.7	66	-0.08	1.05	-1.9	-0.13	2.3
	Week 40	65	10.86	0.82	8.6	10.90	12.3	65	-0.09	1.02	-2.2	-0.10	2.7
	Week 42	62	10.89	0.81	9.3	10.85	12.5	62	-0.11	0.96	-2.6	-0.05	1.8
	Week 44	61	11.02	0.86	9.5	10.70	14.1	61	0.03	0.99	-1.9	-0.10	2.3
	Week 46	61	11.01	0.83	9.3	10.90	13.6	61	0.02	0.94	-2.0	0.03	1.8
	Week 48	61	10.94	0.83	9.3	10.90	12.3	61	-0.04	0.97	-2.4	0.03	1.8
	Week 50	61	11.07	1.03	9.4	10.90	15.2	61	0.08	1.10	-2.2	0.17	3.4
	Week 52	61	11.07	0.97	8.8	11.10	14.1	61	0.09	1.06	-2.8	0.20	3.3
	Evaluation period	86	10.65	1.19	7.1	10.88	12.2	86	-0.23	1.26	-3.8	-0.09	2.1
	End of Follow-Up	84	10.65	1.00	8.0	10.60	13.4	84	-0.24	1.17	-2.4	-0.27	3.4

Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: Total

		Value at visit						Change from Baseline					
Planned Treatment	Visit	n	Mean	SD	Min	Median	Max	n	Mean	SD	Min	Median	Max
Darbepoetin alfa (N=35)	Screening -4	1	12.40	.	12.4	12.40	12.4						
	Screening -3	5	11.18	0.72	10.1	11.50	11.8						
	Screening -2	35	11.09	0.77	9.5	11.20	12.5						
	Screening -1	35	11.03	0.61	9.7	11.10	12.1						
	Week 0	35	11.00	0.65	9.2	11.00	12.4						
	Baseline	35	11.04	0.62	9.6	11.17	12.0						
	Week 2	35	10.99	0.64	9.8	11.00	12.5	35	-0.05	0.47	-1.0	-0.03	0.9
	Week 4	34	10.95	0.71	9.2	11.00	12.3	34	-0.08	0.57	-2.0	0.02	0.9
	Week 6	34	10.96	0.74	9.6	11.05	12.2	34	-0.07	0.76	-1.6	0.03	1.5
	Week 8	33	10.96	0.81	8.9	11.00	12.7	33	-0.05	0.93	-2.6	-0.07	2.0
	Week 10	33	10.73	0.89	8.0	10.90	12.2	33	-0.27	1.18	-3.5	-0.17	1.7
	Week 12	33	10.80	0.88	8.6	10.90	12.2	33	-0.21	1.17	-2.9	-0.17	2.0
	Week 14	31	10.95	0.83	8.3	11.10	12.1	31	-0.03	1.06	-3.2	-0.03	1.8
	Week 16	31	10.96	0.79	9.2	11.10	12.2	31	-0.02	1.10	-2.7	0.13	2.0
	Week 18	30	11.03	0.78	9.4	11.20	12.6	30	0.08	1.04	-1.9	0.15	1.8
	Week 20	31	10.95	0.74	9.3	11.10	12.2	31	-0.03	1.07	-2.2	-0.03	2.3
	Week 22	31	10.91	0.69	9.6	11.00	11.9	31	-0.07	0.79	-1.6	0.03	1.5
	Week 24	31	10.77	1.08	6.7	10.90	12.3	31	-0.21	1.15	-4.6	-0.13	1.9
	Week 26	31	10.82	0.90	7.7	10.90	13.0	31	-0.16	1.00	-3.6	0.03	1.5
	Week 28	31	10.98	0.87	8.8	10.90	13.6	31	0.00	0.96	-2.5	0.07	2.1
	Week 30	31	10.89	0.85	9.0	10.80	13.2	31	-0.09	1.05	-2.0	-0.17	2.0
	Week 32	31	10.93	0.70	9.1	10.90	12.4	31	-0.05	0.93	-1.8	0.00	1.7
	Week 33	31	10.95	0.81	9.2	11.00	12.6	31	-0.03	0.98	-2.4	0.10	1.9
	Week 34	31	10.92	0.76	9.2	11.00	12.6	31	-0.06	1.08	-2.8	-0.03	2.2
	Week 35	31	10.99	0.79	9.1	10.90	12.8	31	0.01	1.04	-2.9	0.07	2.3
	Week 36	31	10.92	0.79	9.5	10.90	12.6	31	-0.06	1.07	-2.5	-0.03	2.3
	Week 38	31	10.90	0.80	9.6	10.90	13.1	31	-0.08	1.04	-1.8	-0.13	3.5
	Week 40	31	10.69	0.84	9.1	10.70	12.3	31	-0.29	0.92	-1.9	-0.30	2.0
	Week 42	31	10.52	0.93	8.7	10.50	12.2	31	-0.46	1.05	-2.5	-0.43	2.1
	Week 44	31	10.67	0.96	8.5	10.60	12.4	31	-0.31	1.15	-2.7	-0.23	2.8
	Week 46	31	10.65	0.96	8.4	10.70	13.1	31	-0.33	1.16	-2.8	-0.23	2.0
	Week 48	31	10.68	0.95	8.8	10.70	12.3	31	-0.30	1.20	-2.5	-0.33	2.6
	Week 50	30	10.95	0.70	9.3	11.10	12.2	30	-0.01	0.97	-2.1	0.20	2.2
	Week 52	29	10.89	0.73	9.6	10.90	12.3	29	-0.06	0.91	-2.2	-0.13	1.6
	Evaluation period	35	10.92	0.76	9.3	11.05	12.2	35	-0.12	1.01	-2.6	-0.05	2.0
	End of Follow-Up	33	10.68	0.96	8.4	10.60	12.5	33	-0.31	1.01	-2.6	-0.48	1.5

The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0
Screening - X: the Xth last Hb level of scheduled visit during screening period

Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: Total

		Value at visit						Change from Baseline					
Planned Treatment	Visit	n	Mean	SD	Min	Median	Max	n	Mean	SD	Min	Median	Max
Molidustat (N=19)	Screening -3	2	10.15	1.77	8.9	10.15	11.4						
	Screening -2	19	10.77	0.85	9.3	10.90	11.9						
	Screening -1	19	10.66	0.66	9.6	10.60	11.9						
	Week 0	19	10.72	0.83	9.0	10.90	12.1						
	Baseline	19	10.71	0.74	9.5	10.70	11.9						
	Week 2	19	10.87	1.00	8.6	10.80	12.7	19	0.17	0.52	-1.0	0.13	1.1
	Week 4	19	10.86	1.06	8.2	11.10	12.5	19	0.16	0.71	-1.4	0.10	1.4
	Week 6	19	11.12	1.18	8.1	11.40	12.8	19	0.41	0.78	-1.5	0.50	1.5
	Week 8	19	11.13	1.22	8.5	11.30	12.8	19	0.42	0.89	-1.1	0.53	2.3
	Week 10	19	11.15	1.13	8.6	11.70	12.3	19	0.44	0.90	-1.4	0.60	2.1
	Week 12	19	11.31	1.54	7.9	11.80	13.5	19	0.60	1.31	-1.7	0.70	3.3
	Week 14	19	11.28	1.43	8.7	11.90	12.9	19	0.58	1.27	-2.5	0.73	2.6
	Week 16	19	11.47	1.51	8.2	12.10	14.1	19	0.77	1.23	-1.3	0.70	2.9
	Week 18	19	11.23	1.27	8.6	11.70	12.6	19	0.52	1.06	-1.1	0.60	2.5
	Week 20	19	11.15	1.33	7.5	11.60	13.2	19	0.45	1.09	-2.0	0.60	2.2
	Week 22	19	10.87	1.26	7.0	11.20	12.7	19	0.17	1.01	-2.5	0.43	1.7
	Week 24	19	11.09	1.33	7.7	11.50	13.3	19	0.39	1.16	-1.8	0.53	2.3
	Week 26	19	11.16	1.02	9.7	11.10	13.1	19	0.46	1.00	-1.3	0.37	2.1
	Week 28	19	11.00	1.12	8.7	10.80	13.4	19	0.29	1.27	-2.0	0.57	2.4
	Week 30	19	11.14	1.22	8.7	11.30	13.2	19	0.43	1.36	-1.9	0.70	2.3
	Week 32	19	11.25	1.02	9.3	11.00	12.7	19	0.55	1.29	-1.7	0.77	2.4
	Week 33	19	11.17	1.03	9.4	11.00	13.1	19	0.47	1.29	-1.6	0.77	2.3
	Week 34	19	11.26	1.00	9.8	11.30	13.2	19	0.56	1.26	-2.1	0.90	2.4
	Week 35	19	11.36	0.94	9.9	11.40	13.5	19	0.65	1.32	-1.9	0.60	3.2
	Week 36	19	11.34	0.84	9.7	11.30	13.0	19	0.63	1.25	-2.2	0.87	2.9
	Week 38	19	11.22	0.80	9.9	11.10	12.7	19	0.51	1.10	-2.0	0.57	2.1
	Week 40	19	11.16	0.90	9.5	11.20	12.9	19	0.45	1.15	-1.6	0.40	2.1
	Week 42	19	11.31	0.99	10.1	11.20	13.4	19	0.60	1.13	-1.8	0.63	2.8
	Week 44	19	11.23	0.71	10.1	11.00	12.7	19	0.52	1.04	-1.1	0.67	2.4
	Week 46	19	11.24	0.83	9.9	11.30	12.9	19	0.53	1.15	-1.6	0.63	2.4
	Week 48	19	11.44	0.94	10.2	11.10	13.7	19	0.73	1.23	-1.0	0.63	4.1
	Week 50	19	11.13	0.89	9.5	10.90	12.7	19	0.42	1.13	-1.5	0.37	3.0
	Week 52	19	11.04	1.05	8.0	11.10	12.8	19	0.33	1.05	-1.5	0.47	2.7
	Evaluation period	19	11.28	0.91	9.8	11.30	13.2	19	0.58	1.25	-2.0	0.87	2.7
	End of Follow-Up	19	10.82	1.16	8.7	10.70	12.5	19	0.11	1.31	-2.1	0.30	2.8

Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: Total

		Value at visit						Change from Baseline					
Planned Treatment	Visit	n	Mean	SD	Min	Median	Max	n	Mean	SD	Min	Median	Max
Darbepoetin alfa (N=9)	Screening -3	2	10.75	0.64	10.3	10.75	11.2						
	Screening -2	9	10.64	0.72	9.7	10.30	12.1						
	Screening -1	9	10.81	0.58	10.2	10.60	11.6						
	Week 0	9	10.72	1.01	9.5	10.50	12.1						
	Baseline	9	10.72	0.72	9.8	10.43	11.9						
	Week 2	8	10.78	1.11	9.0	10.80	12.2	8	0.12	0.60	-0.8	0.05	0.9
	Week 4	8	10.79	1.12	8.9	10.80	12.0	8	0.13	0.62	-0.9	0.05	1.1
	Week 6	8	11.05	1.14	9.3	10.95	12.6	8	0.40	0.63	-0.5	0.20	1.4
	Week 8	8	10.88	1.01	9.4	10.70	12.2	8	0.22	0.54	-0.4	0.15	0.9
	Week 10	8	10.70	1.12	9.2	10.75	11.9	8	0.05	0.69	-1.1	0.15	0.9
	Week 12	8	10.84	0.79	9.2	11.05	11.6	8	0.18	0.68	-0.6	0.05	1.4
	Week 14	8	10.60	0.79	9.4	10.55	11.9	8	-0.05	0.69	-0.8	-0.23	0.9
	Week 16	8	10.59	0.58	9.9	10.60	11.5	8	-0.07	0.82	-1.3	0.07	1.1
	Week 18	8	10.63	1.08	8.6	10.75	12.2	8	-0.03	1.42	-2.4	0.07	2.0
	Week 20	8	10.30	0.97	8.3	10.30	11.4	8	-0.35	1.22	-2.7	-0.12	1.3
	Week 22	8	10.30	0.70	8.7	10.55	10.8	8	-0.35	1.16	-2.3	0.00	0.7
	Week 24	8	10.13	0.63	9.1	10.30	10.8	8	-0.53	1.07	-1.9	-0.37	0.7
	Week 26	8	10.44	0.66	9.4	10.60	11.2	8	-0.22	1.08	-1.6	-0.27	1.0
	Week 28	8	10.74	0.62	9.4	10.85	11.4	8	0.08	1.00	-1.1	-0.05	1.3
	Week 30	8	10.50	0.91	8.5	10.65	11.5	8	-0.15	1.14	-1.9	-0.27	1.4
	Week 32	8	10.80	1.06	9.0	11.00	12.2	8	0.15	1.27	-1.4	-0.10	2.1
	Week 33	8	11.11	1.03	9.6	10.90	12.8	8	0.46	1.35	-0.9	0.32	2.5
	Week 34	8	10.89	1.18	9.5	10.70	12.7	8	0.23	1.48	-0.9	-0.28	2.9
	Week 35	8	10.81	0.87	9.5	10.70	12.1	8	0.16	1.22	-0.9	-0.23	2.3
	Week 36	8	10.84	0.63	10.1	10.80	11.9	8	0.18	1.09	-1.4	-0.03	2.1
	Week 38	8	10.91	0.87	10.0	11.05	12.6	8	0.26	1.25	-1.5	0.07	2.8
	Week 40	8	11.01	0.83	10.1	10.85	12.2	8	0.36	1.27	-1.4	0.20	2.4
	Week 42	8	10.95	0.78	9.7	10.90	11.9	8	0.30	1.10	-1.2	0.15	2.1
	Week 44	8	10.69	0.81	9.6	10.65	11.9	8	0.03	0.85	-1.1	-0.27	1.5
	Week 46	8	10.70	0.81	9.6	10.60	12.1	8	0.05	0.91	-1.0	-0.27	1.7
	Week 48	8	10.84	0.85	9.6	10.70	12.3	8	0.18	0.95	-0.9	0.07	1.9
	Week 50	8	11.08	0.72	9.7	11.05	11.9	8	0.42	0.76	-0.4	0.35	1.5
	Week 52	8	11.13	0.63	9.7	11.25	11.8	8	0.47	0.83	-0.5	0.42	1.7
	Evaluation period	9	10.70	1.05	9.0	10.58	12.2	9	-0.02	1.44	-2.3	-0.08	2.4
	End of Follow-Up	9	10.69	1.11	8.8	10.90	12.7	9	-0.03	1.32	-2.2	-0.07	2.6

The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0
Screening - X: the Xth last Hb level of scheduled visit during screening period

Last Erythropoiesis-Stimulating Agent treatment: Epoetin alfa or beta
Categories: Total

		Value at visit						Change from Baseline					
Planned Treatment	Visit	n	Mean	SD	Min	Median	Max	n	Mean	SD	Min	Median	Max
Molidustat (N=48)	Screening -3	3	11.13	0.35	10.8	11.10	11.5						
	Screening -2	48	10.66	0.60	9.2	10.60	12.1						
	Screening -1	48	10.60	0.63	9.2	10.55	12.0						
	Week 0	48	10.51	0.62	9.0	10.45	11.8						
	Baseline	48	10.60	0.55	9.5	10.55	11.8						
	Week 2	48	10.37	0.84	8.5	10.30	12.4	48	-0.22	0.70	-2.1	-0.34	1.7
	Week 4	47	10.26	1.30	7.3	10.20	13.4	47	-0.34	1.19	-3.3	-0.48	2.5
	Week 6	47	10.31	1.48	7.4	10.30	13.7	47	-0.29	1.38	-3.1	-0.17	2.8
	Week 8	42	10.64	1.48	7.5	10.35	14.2	42	0.01	1.41	-2.4	-0.03	3.3
	Week 10	43	10.71	1.56	7.1	10.60	13.7	43	0.09	1.50	-3.1	0.37	2.8
	Week 12	41	10.91	1.41	8.1	10.80	14.0	41	0.31	1.34	-2.6	0.47	3.1
	Week 14	41	10.95	1.33	8.3	10.80	13.9	41	0.34	1.27	-2.9	0.53	3.2
	Week 16	41	10.97	1.25	8.0	11.10	13.4	41	0.36	1.27	-3.5	0.60	2.7
	Week 18	41	10.99	1.10	8.3	11.30	12.8	41	0.39	1.15	-3.3	0.57	2.3
	Week 20	41	11.05	0.91	8.7	11.30	12.7	41	0.44	0.99	-2.9	0.67	2.5
	Week 22	40	11.09	1.00	8.6	11.25	13.5	40	0.48	1.15	-3.0	0.60	3.1
	Week 24	40	10.99	1.00	8.2	11.10	13.3	40	0.38	1.13	-3.4	0.47	2.9
	Week 26	39	11.02	0.90	9.1	11.30	12.5	39	0.41	1.02	-2.3	0.47	2.1
	Week 28	38	11.00	0.85	8.9	11.20	12.8	38	0.39	0.99	-2.7	0.57	1.8
	Week 30	37	10.89	0.87	8.9	11.10	12.4	37	0.27	1.11	-2.7	0.50	2.7
	Week 32	38	10.94	0.89	9.4	11.15	12.5	38	0.33	1.08	-2.2	0.70	1.9
	Week 33	37	10.99	0.93	9.2	11.00	12.9	37	0.38	1.09	-2.3	0.60	2.2
	Week 34	37	10.94	0.91	8.9	11.00	13.1	37	0.32	1.11	-2.2	0.40	2.4
	Week 35	37	11.01	0.97	8.9	11.20	12.7	37	0.39	1.13	-2.2	0.73	2.1
	Week 36	37	10.98	0.87	9.0	11.20	12.4	37	0.36	1.08	-2.4	0.47	2.1
	Week 38	37	10.89	0.87	8.7	11.00	12.2	37	0.28	1.11	-2.4	0.37	2.7
	Week 40	37	10.94	0.98	7.8	10.90	12.8	37	0.33	1.24	-3.3	0.43	3.0
	Week 42	36	11.05	0.84	9.6	10.95	13.3	36	0.44	1.11	-1.8	0.15	3.2
	Week 44	36	10.97	0.90	9.4	10.80	12.7	36	0.36	1.15	-1.7	0.20	3.2
	Week 46	35	11.08	0.82	9.7	11.10	12.6	35	0.48	1.09	-1.5	0.23	2.9
	Week 48	34	10.99	0.77	9.8	10.95	13.0	34	0.36	1.01	-1.3	0.17	2.8
	Week 50	34	11.12	0.75	9.9	10.95	13.4	34	0.49	0.97	-1.1	0.47	3.2
	Week 52	34	10.93	0.87	9.4	10.80	13.0	34	0.30	1.04	-1.1	0.05	3.0
	Evaluation period	48	10.34	1.63	4.8	10.78	12.8	48	-0.26	1.70	-6.1	0.30	2.1
	End of Follow-Up	48	10.71	1.30	7.6	10.90	12.9	48	0.12	1.40	-2.8	0.37	2.4

Last Erythropoiesis-Stimulating Agent treatment: Epoetin alfa or beta
Categories: Total

		Value at visit						Change from Baseline					
Planned Treatment	Visit	n	Mean	SD	Min	Median	Max	n	Mean	SD	Min	Median	Max
Darbepoetin alfa (N=32)	Screening -6	1	9.20	.	9.2	9.20	9.2						
	Screening -5	1	9.00	.	9.0	9.00	9.0						
	Screening -4	2	10.75	1.77	9.5	10.75	12.0						
	Screening -3	5	11.12	0.95	9.6	11.50	12.1						
	Screening -2	32	10.82	0.58	9.9	10.80	11.9						
	Screening -1	32	10.65	0.71	9.3	10.50	12.4						
	Week 0	32	10.57	0.77	9.2	10.40	12.8						
	Baseline	32	10.67	0.64	9.5	10.50	11.9						
	Week 2	31	10.71	0.73	9.3	10.60	13.1	31	0.03	0.47	-1.0	-0.07	1.2
	Week 4	30	10.68	0.52	9.8	10.65	11.9	30	0.04	0.56	-1.2	0.03	1.4
	Week 6	30	10.83	0.64	9.6	10.65	12.3	30	0.19	0.76	-1.0	0.15	2.3
	Week 8	30	11.04	0.52	10.2	10.95	12.2	30	0.39	0.79	-1.3	0.35	2.2
	Week 10	30	11.08	0.51	10.2	11.05	12.1	30	0.44	0.79	-1.2	0.48	2.1
	Week 12	30	11.06	0.66	9.7	11.05	12.8	30	0.41	0.97	-1.6	0.35	2.8
	Week 14	30	11.07	0.79	9.1	11.10	12.1	30	0.43	1.08	-2.1	0.48	2.3
	Week 16	30	11.11	0.82	8.7	11.25	12.4	30	0.46	1.14	-2.6	0.48	2.6
	Week 18	30	11.02	0.81	8.7	11.05	12.3	30	0.38	1.17	-2.6	0.43	2.1
	Week 20	30	10.94	1.06	8.4	10.90	13.4	30	0.30	1.27	-2.5	0.47	2.9
	Week 22	30	10.90	0.95	9.0	10.90	13.4	30	0.26	1.12	-2.2	0.45	3.0
	Week 24	30	10.67	0.97	8.6	10.65	12.3	30	0.03	1.06	-2.7	0.27	1.4
	Week 26	30	10.63	1.02	8.4	10.75	12.4	30	-0.01	1.06	-1.9	0.05	1.9
	Week 28	30	10.53	1.00	8.6	10.50	12.8	30	-0.11	1.08	-2.1	0.10	2.4
	Week 30	29	10.62	0.85	9.1	10.50	12.5	29	-0.01	0.96	-1.7	0.07	2.1
	Week 32	29	10.50	0.68	9.1	10.60	11.9	29	-0.13	0.72	-1.8	-0.20	1.1
	Week 33	28	10.66	0.56	9.6	10.65	11.7	28	0.03	0.80	-1.9	0.03	1.7
	Week 34	28	10.68	0.63	9.7	10.45	12.0	28	0.04	0.87	-2.2	-0.05	1.8
	Week 35	28	10.71	0.71	9.7	10.55	12.6	28	0.07	0.98	-1.9	0.10	2.6
	Week 36	28	10.75	0.79	9.6	10.55	12.7	28	0.11	1.06	-2.0	0.10	2.7
	Week 38	28	10.83	0.78	9.5	10.60	12.7	28	0.19	1.06	-1.9	0.18	2.7
	Week 40	28	10.76	0.85	9.4	10.75	12.4	28	0.12	1.15	-2.1	0.07	2.8
	Week 42	28	10.70	0.79	9.0	10.85	12.1	28	0.06	1.02	-2.3	-0.03	2.5
	Week 44	28	10.81	0.87	8.9	10.85	12.6	28	0.17	1.06	-2.0	0.22	2.5
	Week 46	28	10.77	0.73	9.4	10.90	11.8	28	0.13	0.84	-1.4	0.27	1.5
	Week 48	28	10.83	0.88	9.4	11.00	12.5	28	0.19	0.87	-1.9	0.27	1.3
	Week 50	28	10.91	0.67	9.5	10.85	12.0	28	0.27	0.71	-1.2	0.20	1.5
	Week 52	28	10.83	0.72	9.6	10.75	12.6	28	0.19	0.73	-1.7	0.15	1.4
	Evaluation period	32	10.63	0.70	9.0	10.55	12.2	32	-0.04	0.88	-2.0	0.10	2.2
	End of Follow-Up	32	10.29	0.94	8.2	10.30	11.8	32	-0.37	0.86	-2.1	-0.38	1.5

The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0
Screening - X: the Xth last Hb level of scheduled visit during screening period